Irritable bowel syndrome (IBS) is common, but reported prevalence varies substantially by country, survey population, and diagnostic criteria. Available studies put overall prevalence around 10% to 12% in several broad populations, while individual estimates range from 1.1% to 45.0%. The figures below show why measurement method and population matter when interpreting IBS statistics.
Contents
- How common is IBS?
- What prevalence studies show
- Who is more likely to report IBS?
- Diagnosis and symptom subtypes
- Symptoms and daily-life impact
- Related conditions and healthcare use
How common is IBS?
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that about 12% of people in the United States have IBS. NIDDK also reports that women can be up to twice as likely as men to develop IBS, and that people younger than 50 are more likely to develop it than people older than 50. These are broad summary estimates rather than results from one single survey.
A global meta-analysis in PubMed 22426087 found a pooled IBS prevalence of 11.2%. Across the countries and study settings included in that analysis, prevalence ranged from 1.1% to 45.0%. The analysis screened 390 citations, included 81 prevalence reports, and covered 80 separate study populations. Altogether, those reports represented 260,960 subjects.
The wide range does not mean that one population necessarily became several dozen times more likely to have IBS. It reflects differences in study design, populations, countries, and diagnostic definitions. The same meta-analysis produced different estimates when it applied different symptom criteria.
| Population or measurement | IBS estimate | Source |
|---|---|---|
| United States, broad NIDDK estimate | About 12% | NIDDK |
| Global pooled estimate | 11.2% | PubMed 22426087 |
| International European survey | 11.5% overall | PubMed 12641512 |
| US community survey | 14.1% total | PubMed 15932367 |
| Community survey | 10.5% overall | PubMed 15239910 |
| Community-based cohort | 18.6% | PubMed 38576370 |
| UK population subtype study | 6% | PubMed 25076066 |
What prevalence studies show
The 14.1% estimate in the US community survey in PubMed 15932367 included two different groups: 3.3% had medically diagnosed IBS, while 10.8% had not been diagnosed but tested positive under the study’s Rome criteria. In that survey, 76.6% of people classified as IBS sufferers were undiagnosed. This distinction is important: the number of people who meet symptom criteria can be much larger than the number who report a formal diagnosis.
The same US survey found that 74% of medically diagnosed sufferers reported alternating constipation and diarrhea. Among undiagnosed sufferers, 63% reported that same alternating pattern. Participants with IBS reported 6.4 days off work, compared with 3.0 days among non-sufferers in that survey.
An international European survey reported 11.5% overall prevalence in PubMed 12641512. Its component measures were lower or higher depending on the definition: 9.6% reported current symptoms, 4.8% had been formally diagnosed, 2.9% met Rome II criteria, 4.2% met Rome I criteria, and 6.5% met Manning criteria.
The global meta-analysis also demonstrated this measurement effect. Prevalence was 14.0% when at least three Manning criteria were used, 8.8% under Rome I criteria, and 9.4% under Rome II criteria. These are estimates from the included reports, not interchangeable measurements of exactly the same case definition.
Other community studies produced different results. A community survey reported 10.5% prevalence in PubMed 15239910. A community-based cohort of 16,252 participants reported 18.6% prevalence and identified 3,025 IBS cases in PubMed 38576370. A UK population study reported 6% prevalence in PubMed 25076066.
Who is more likely to report IBS?
Sex and age differences appear repeatedly, although the size of the difference varies by study. The community survey in PubMed 15239910 reported prevalence of 6.6% among men and 14.0% among women. The community-based cohort in PubMed 38576370 reported 15.5% prevalence in men and 19.9% in women.
In the global meta-analysis, women had higher odds of IBS than men, with an odds ratio of 1.67. Adults over 50 had lower odds than younger adults, with an odds ratio of 0.75. NIDDK’s summary similarly states that women can be up to twice as likely as men to develop IBS and that people younger than 50 are more likely than older people to develop it.
The figures describe associations in particular populations. They do not establish that sex or age alone causes IBS, and the estimates should not be treated as a personal risk calculation.
Diagnosis and symptom subtypes
IBS is commonly described by bowel-pattern subtype. In a Rome III outpatient study of 754 people, reported in PubMed 21929652, 66.3% had IBS with diarrhea (IBS-D), 14.7% had IBS with constipation (IBS-C), 4.2% had mixed IBS (IBS-M), and 14.8% had unsubtyped IBS (IBS-U). In that study, 97.5% met Rome III criteria, while 65.3% met both Rome II and Rome III criteria.
The distribution was different in a Canadian patient-experience survey published through Oxford Academic. The survey had 2,470 qualified respondents filtered from 2,981 total responses. IBS-M represented 44% of respondents, IBS-D 37.1%, and IBS-C 18.9%. Women made up 88% of respondents, so these percentages describe that patient survey rather than the general Canadian population.
A UK population subtype study in PubMed 25076066 found that IBS-C patients averaged 45 years of age, compared with 30 years among IBS-D patients. The study recorded 56 additional investigations among IBS-C patients, averaging 0.88 investigations per patient. IBS-D patients underwent 734 additional investigations, averaging 2.2 per patient. Further testing found an alternative diagnosis in 22% of IBS-D patients and 0% of IBS-C patients in that study.
These subtype figures are not directly comparable because the studies used different populations and settings: one examined outpatients, one surveyed Canadian patients, and one analyzed a UK population dataset.
Symptoms and daily-life impact
The Canadian survey shows how symptom burden differed across subtypes. Moderate-to-severe abdominal pain was reported by 63% to 70% across subtypes, while moderate-to-severe bloating was reported by 59% to 75%. Severe bloating affected 32% of IBS-C respondents. Within IBS-C, severe straining was reported by 72% and severe tenesmus by 78%.
Among IBS-D respondents, severe urgency was reported by 63% and incontinence by 29%. Symptoms interfered with daily life sometimes for 46% of all respondents and often for 23%. Between 51% and 56% had lived with IBS for more than 10 years, depending on the subtype group.
| Finding in the Canadian patient survey | Reported percentage |
|---|---|
| Moderate-to-severe abdominal pain, across subtypes | 63%–70% |
| Moderate-to-severe bloating, across subtypes | 59%–75% |
| Severe bloating, IBS-C | 32% |
| Severe straining, IBS-C | 72% |
| Severe tenesmus, IBS-C | 78% |
| Severe urgency, IBS-D | 63% |
| Incontinence, IBS-D | 29% |
| Daily-life interference sometimes | 46% |
| Daily-life interference often | 23% |
The same survey reported mood disorders in 30% to 34% of respondents and anxiety disorders in 25% to 30%. These results describe reported coexisting conditions in the survey and do not show that IBS caused those conditions.
Related conditions and healthcare use
The Canadian survey also measured selected comorbidities. GERD was reported by 23% of IBS-D respondents and 31% of IBS-M respondents. Sleep disorders were reported by 20% of IBS-D respondents, 28% of IBS-M respondents, and 27% of IBS-C respondents.
Healthcare use varied by subtype. In the year before the survey, 29% of IBS-D respondents reported visiting a healthcare provider zero times. Regular treatment use also differed: one regular treatment was reported by 32% of IBS-M respondents, 44% of IBS-D respondents, and 28% of IBS-C respondents.
Dietary changes were common across the three Canadian subtype groups: 71% of IBS-M respondents, 72% of IBS-D respondents, and 72% of IBS-C respondents reported using them. Low-FODMAP use was reported by 11% of IBS-C respondents and 7% of IBS-D respondents. Probiotic use was 34% among IBS-C respondents and 26% among IBS-D respondents.
Prior or current laxative use was reported by 43% of IBS-C respondents, 35% of IBS-M respondents, and 13% of IBS-D respondents. Because these figures come from a patient-experience survey, they indicate reported patterns within that sample; they are not treatment recommendations or estimates for every person with IBS.